<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>HU-211, a nonpsychotropic cannabinoid and a noncompetitive <z:chebi fb="0" ids="31882">NMDA</z:chebi> <z:chebi fb="68" ids="48706">antagonist</z:chebi>, was tested in a global <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> model in the Mongolian gerbil </plain></SENT>
<SENT sid="1" pm="."><plain>Male Mongolian gerbils underwent a 10-min bilateral common carotid <z:mp ids='MP_0006134'>artery occlusion</z:mp> </plain></SENT>
<SENT sid="2" pm="."><plain>HU-211, administered i.v. at 4 mg/kg, 30 min postischemia, induced statistically significant neuroprotection of the CA1 subfield of the hippocampus </plain></SENT>
<SENT sid="3" pm="."><plain>A dose-response study demonstrated an inverted U curve in which the 4 mg/kg dose induced the best neuroprotection in the CA1 subfield of the hippocampus (p &lt; 0.05 ANOVA followed by Duncan's post-hoc test) </plain></SENT>
<SENT sid="4" pm="."><plain>The therapeutic window was then investigated, and in another study, HU-211 4 mg/kg were administered i.v. at 30, 60, 120, and 180 min postinsult </plain></SENT>
<SENT sid="5" pm="."><plain>A statistically significant neuroprotection was detected at 30 and 60 min administration postinsult </plain></SENT>
</text></document>